High-rolling investors have positioned themselves bullish on Biogen (NASDAQ:BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...

We recently published a list of 12 Best Scientific Instruments Stocks to Buy Right Now. In this article, we are going to take a look at where Agilent Technologies Inc. (NYSE:A) stands against ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.

Deep-pocketed investors have adopted a bullish approach towards Biogen BIIB, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet ...